EPRX
Eupraxia Pharmaceuticals Inc.Company with tickers: EPRX
CIK
1581178
CUSIP
29842P105
Shares Outstanding
65,326,947
13F Activity (30d)
52 filings
52 filers
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | $0 | USD | 2025-12-31 | 40-F | 2026-03-13 |
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $38,434,039 | USD | 2025-12-31 | 40-F | 2026-03-13 |
| Research & Development | $21,331,656 | USD | 2025-12-31 | 40-F | 2026-03-13 |
| Operating Income | — | ||||
| Net Income | $-38,576,143 | USD | 2025-12-31 | 40-F | 2026-03-13 |
| EPS (Basic) | $-1.03 | USD/shares | 2025-12-31 | 40-F | 2026-03-13 |
| EPS (Diluted) | $-1.03 | USD/shares | 2025-12-31 | 40-F | 2026-03-13 |